FDA approves Orexo’s Zubsolv as opioid dependence maintenance therapy
Indicated for use as part of a complete treatment plan, including counseling and psychosocial support, the once-daily, sublingual tablet is an advanced formulation of buprenorphine and naloxone. Expected